2Buzello M, Tornig J, Faulhaber J, et al.The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia.J Am Soc Nephrol,2003,14:311-316.
3Mann JF, Gerstein HC, Dulau-Florea I,et al.Cardiovascular risk in patients with mild renal insufficiency.Kidney Int Suppl,2003,(84):S192-S196.
4Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem.J Am Soc Nephrol,2003,14:1927-1939.
5Drueke T, Witko-Sarsat V, Massy Z,et al.Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease.Circulation,2002,106:2212-2217.
6Pecoits-Filho R, Stenvinkel P, Marchlewska A,et al.A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients.Kidney Int Suppl,2003,(84):S172-S176.
7Boaz M, Smetana S, Weinstein T,et al.Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.Lancet,2000,356:1213-1218.
8Tepel M, van der Giet M, Statz M, et al.The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial.Circulation,2003,107:992-995.
9Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy.Semin Dial,2002,15:329-337.
10Venugopal SK, Devaraj S, Yuhanna I, et al.Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells.Circulation,2002,106:1439-1441.
